Market Intelligence, Clinical Progress, and High-Purity Reagents for Integrin Alpha-7 Target Validation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ITGA7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGA7 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ITGA7 Products |
| Gene Delivery | ITGA7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View ITGA7 Products |
| Benchmark Ab | Anti-ITGA7 Recombinant Antibody Recombinant positive control for binding and internalization assays. |
View ITGA7 Products |
| Validator | ITGA7 siRNA Set For knockdown verification in target-specificity assays. |
View ITGA7 Products |
| Related Target A | ITGB1 (Integrin Beta-1) Required heterodimerization partner for functional ITGA7 signaling. |
View ITGB1 Products |
| Related Target B | LAMA2 (Laminin Subunit Alpha-2) Primary extracellular matrix ligand for ITGA7/ITGB1 complex. |
View LAMA2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Heterodimerization (ITGA7/ITGB1) | Lentivirus Premade Particles for stable co-expression in host cell lines, preserving native conformation. |
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cynomolgus recombinant ortholog proteins available with >95% purity. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included for functional validation. |
| False Positives / Off-target Binding | Sequence-verified ITGA7 siRNA knockdown pool included for target specificity verification. |
Live ITGA7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ITGA7 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and target-stabilizing therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting cancer stem cell (CSC) niches and muscular dystrophy indications where ITGA7 expression is highly modulated.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Oncology Biotechs | Glioblastoma, Melanoma | Internalization Assay (Need high-purity HEK293-expressed ECD-Fc) |
| Monoclonal Antibody (Blocking) | Academic Medical Centers | Solid Tumors, Metastasis | Ligand-blocking assays (Need high-purity LAMA2 and ITGA7/ITGB1 complex) |
| Gene Therapy / Up-regulation | Rare Disease Therapeutics | Muscular Dystrophy | Stable cell lines (Need Lentivirus for long-term expression validation) |